The FN13 peptide inhibits human tumor cells invasion through the modulation of αvβ3 integrins organization and the inactivation of ILK pathway

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1773, Issue 6, 2007, Pages 747-763

  Zoppi, Nicoletta ^a   Ritelli, Marco ^a   Salvi, Alessandro ^a   Colombi, Marina ^a   Barlati, Sergio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

v 3 integrin; Extracellular matrix; Fibronectin; FN13 peptide; ILK; Tumor cells invasion

Indexed keywords

ALPHAVBETA1 INTEGRIN; ALPHAVBETA5 INTEGRIN; CYCLOHEXIMIDE; FIBRONECTIN; FIBRONECTIN 13; FIBRONECTIN RECEPTOR; GELATINASE B; INTEGRIN; INTEGRIN LINKED KINASE; INTEGRIN RECEPTOR; MATRIGEL; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MEMBRANE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NEUROBLASTOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR CELL;

CELL LINE, TUMOR; CELL MEMBRANE; DIMERIZATION; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 34249717427     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.02.007     Document Type: Article

References (53)

1. Yamada K.M. Fibronectin domains and receptors. In: Mosher D.F. (Ed). Fibronectin (1989), Academic A., Press, San Diego 47-121
2. Vartio T., and Vaheri Keski-Oja J. Fibronectin and malignant transformation. In: Mosher D.F. (Ed). Fibronectin (1989), Academic A., Press, San Diego 255-271
3. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
4. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 76 (1999) 1-20
5. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
6. Beauvais-Jouneau A., and Thiéry J.P. Multiple roles for integrins during development. Biol. Cell 89 (1997) 5-11
7. Yamada K.M., Pankov R., and Cukierman E. Dimensions and dynamics in integrin function. Braz. J. Med. Biol. Res. 36 (2003) 959-966
8. Vogel B.E., Tarone G., Giancotti F.G., Gailit J., and Ruoslahti E. A novel fibronectin receptor with an unexpected subunit composition (alpha v beta 1). J. Biol. Chem. 265 (1990) 5934-5937
9. Schoenwaelder S.M., and Burridge K. Bidirectional signaling between the cytoskeleton and integrins. Curr. Opin. Cell Biol. 11 (1999) 274-286
10. Critchley D.R. Focal adhesions-The cytoskeletal connection. Curr. Opin. Cell Biol. 12 (2000) 133-139
11. Yamada K.M., Yamada S., and Pastan I. Cell surface protein partially restores morphology, adhesiveness, and contact inhibition of movement to transformed fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 1217-1220
12. Hynes R.O. Cell surface proteins and malignant transformation. Biochim. Biophys. Acta 458 (1976) 73-107
13. Akiyama S.K., Olden K., and Yamada K.M. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 14 (1995) 173-189
14. Mizejewski G.J. Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med. 222 (1999) 124-138
15. Hood J.D., and Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev., Cancer 2 (2002) 91-100
16. Plantefaber L.C., and Hynes R.O. Changes in integrin receptors on oncogenically transformed cells. Cell 561 (1989) 281-290
17. Zutter M.M., Santoro S.A., Staatz W.D., and Tsung Y.L. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7411-7415
18. Weinel R.J., Rosendahl A., Neumann K., Chaloupka B., Erd D., Rothmund M., and Santoso S. Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. Int. J. Cancer 52 (1992) 827-833
19. Tennenbaum T., Yuspa S.H., Grover A., Castronovo V., Sobel M.E., Yamada Y., and De Luca L.M. Extracellular matrix receptors and mouse skin carcinogenesis: altered expression linked to appearance of early markers of tumor progression. Cancer Res. 52 (1992) 2966-2976
20. Stallmach A., von Lampe B.V., Matthes H., Bornhoft G., and Riecken E.O. Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut 33 (1992) 342-346
21. Giancotti F.G., and Ruoslahti E. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60 (1990) 849-859
22. Varner J.A., Emerson D.A., and Juliano R.L. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol. Biol. Cell 6 (1995) 725-740
23. Schreiner C., Fisher M., Hussein S., and Juliano R.L. Increased tumorigenicity of fibronectin receptor deficient Chinese hamster ovary cell variants. Cancer Res. 51 (1991) 1738-1740
24. Albelda S.M., Mette S.A., Elder D.E., Stewart D., Damjanovich L., Herlyn M., and Buck C.A. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 50 (1990) 6757-6764
25. Danen E.H., Jansen K.F., Van Kraats A.A., Cornelissen I.M., Ruiter D.J., and Van Muijen G.N. Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int. J. Cancer 61 (1995) 491-496
26. Koistinen P., Ahonen M., Kahari V.M., and Heino J. AlphaV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma. Int. J. Cancer 112 (2004) 61-70
27. Bartolazzi A., Cerboni C., Nicotra M.R., Mottolese M., Bigotti A., and Natali P.G. Transformation and tumor progression are frequently associated with expression of the alpha 3/beta 1 heterodimer in solid tumors. Int. J. Cancer 58 (1994) 488-491
28. Goldberg I., Davidson B., Reich R., Gotlieb W.H., Ben-Baruch G., Bryne M., Berner A., Nesland J.M., and Kopolovic J. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin. Cancer Res. 7 (2001) 4073-4079
29. Nejjari M., Hafdi Z., Gouysse G., Fiorentino M., Beatrix O., Dumortier J., Pourreyron C., Barozzi C., and Scoazec J.Y. Expression, regulation, and function of alpha V integrins in hepatocellular carcinoma: an in vivo and in vitro study. Hepatology 36 (2002) 418-426
30. Seftor R.E., Seftor E.A., Gehlsen K.R., Stetler-Stevenson W.G., Brown P.D., Ruoslahti E., and Hendrix M.J. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1557-1561
31. Varner J.A., and Cheresh D.A. Integrins and cancer. Curr. Opin. Cell Biol. 8 (1996) 724-730
32. Filardo E.J., Brooks P.C., Deming S.L., Damsky C., and Cheresh D.A. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. Cell Biol. 130 (1995) 441-450
33. Hsu M.Y., Shih D.T., Meier F.E., Van Belle P., Hsu J.Y., Elder D.E., Buck C.A., and Herlyn M. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am. J. Pathol. 153 (1998) 1435-1442
34. Zheng D.Q., Woodard A.S., Fornaro M., Tallini G., and Languino L.R. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 59 (1999) 1655-1664
35. Felding-Habermann B., O'Toole T.E., Smith J.W., Fransvea E., Ruggeri Z.M., Ginsberg M.H., Hughes P.E., Pampori N., Shattil S.J., Saven A., and Mueller B.M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1853-1858
36. Felding-Habermann B., Fransvea E., O'Toole T.E., Manzuk L., Faha B., and Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis 19 (2002) 427-436
37. Carreiras F., Denoux Y., Staedel C., Lehmann M., Sichel F., and Gauduchon P. Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol. Oncol. 62 (1996) 260-267
38. Natali P.G., Hamby C.V., Felding-Habermann B., Liang B., Nicotra M.R., Di Filippo F., Giannarelli D., Temponi M., and Ferrone S. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57 (1997) 1554-1560
39. Gingras M.C., Roussel E., Bruner J.M., Branch C.D., and Moser R.P. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J. Neuroimmunol. 57 (1995) 143-153
40. Pignatelli M., Cardillo M.R., Hanby A., and Stamp G.W. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum. Pathol. 23 (1992) 1159-1166
41. Hannigan G., Troussard A.A., and Dedhar S. Integrin-linked-kinase: a cancer therapeutic target unique among its ILK. Nature Rev. 5 (2005) 51-63
42. Colombi M., Zoppi N., De Petro G., Marchina E., Gardella R., Tavian D., Ferraboli S., and Barlati S. Matrix assembly induction and cell migration and invasion inhibition by a 13-amino acid fibronectin peptide. J. Biol. Chem. 278 (2003) 14346-14355
43. Yi M., and Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 620-624
44. Morla A., Zhang Z., and Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature 367 (1994) 193-196
45. Pasqualini R., Bourdoulous S., Koivunen E., Woods Jr. V.L., and Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nature Med. 2 (1996) 1197-1203
46. Gross N., Beck D., Portoukalian J., Favre S., and Carrel S. New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells. Int. J. Cancer 43 (1989) 665-671
47. Salonen E.-M., Vartio T., Miggiano V., Stähli C., Takacs B., Virgallita G., De Petro G., Barlati S., and Vaheri A. A rapid and highly sensitive solid-phase enzyme immunoassay specific for human fibronectin using a characterized monoclonal antibody. J. Immunol. Methods 72 (1984) 154-156
48. Dean D.C., Bowlus C.L., and Bourgeois S. Cloning and analysis of the promoter region of the human fibronectin gene. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 1876-1880
49. Zoppi N., Gardella R., De Paepe A., Barlati S., and Colombi M. Human fibroblasts with mutations in COL5A1 and COL3A1 genes do not organize collagens and fibronectin in the extracellular matrix, down-regulate alpha2beta1 integrin, and recruit alphavbeta3 instead of alpha5beta1 integrin. J. Biol. Chem. 279 (2004) 18157-18168
50. Cannistra S.A., Ottensmejer C., Niloff J., Orta B., and DiCarlo J. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol. Oncol. 58 (1995) 216-225
51. Strobel T., and Cannistra S.A. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol. Oncol. 73 (1999) 267-362
52. Casey R.C., and Skubitz A.P. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin. Exp. Metastasis 18 (2000) 67-75
53. Carreiras F., Thiebot B., Leroy-Dudal J., Maubant S., Breton M.F., and Darbeida H. Involvement of alphavbeta 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line IGROV1 on the human umbilical vein cell extracellular matrix. Int. J. Cancer 99 (2002) 800-808